Amgen | AMGN - Sales Revenues

Stock Price
367.80
Daily Change
1.60 0.44%
Monthly
11.40%
Yearly
23.51%
Q1 Forecast
331.35

Amgen reported $9.9B in Sales Revenues for its fiscal quarter ending in December of 2025.





Sales Change Date
AbbVie USD 16.62B 840M Dec/2025
Agios Pharmaceuticals USD 12.9M 450K Sep/2025
ALKERMES USD 394.2M 3.5M Sep/2025
Amgen USD 9.9B 340M Dec/2025
Biogen USD 2.53B 70M Sep/2025
BioMarin Pharmaceutical USD 776M 49M Sep/2025
Bristol-Myers Squibb USD 12.5B 300M Dec/2025
Eli Lilly USD 19.3B 1.7B Dec/2025
Exelixis USD 597.8M 29.5M Sep/2025
Genmab DKK 5.86B 580M Jun/2025
Gilead Sciences USD 7.8B 700M Sep/2025
GlaxoSmithKline GBP 8.62B 73M Dec/2025
Glaxosmithkline GBP 11.52B 3.54B Sep/2025
Incyte USD 1.37B 310M Sep/2025
Ionis Pharmaceuticals USD 157M 295M Sep/2025
J&J USD 24.6B 610M Dec/2025
Merck USD 16.4B 880M Dec/2025
Moderna USD 1.02B 878M Sep/2025
Neurocrine Biosciences USD 794.9M 107.4M Sep/2025
Novartis USD 13.91B 144M Sep/2025
Novartis USD 14.36B 478M Sep/2025
Pfizer USD 17.58B 880M Dec/2025
PTC Therapeutics USD 211M 32.1M Sep/2025
Regeneron Pharmaceuticals USD 3.88B 130M Dec/2025
Roche Holding CHF 15.65B 274.5M Dec/2025
Sanofi EUR 11.3B 1.13B Dec/2025
Sarepta Therapeutics USD 399.4M 211.69M Sep/2025
Takeda JPY 1.19T 80B Dec/2025
Teva Pharmaceutical Industries USD 14.63B 10M Dec/2025
Ultragenyx Pharmaceutical USD 160M 6.5M Sep/2025
Vertex Pharmaceuticals USD 3.08B 120M Sep/2025